


Otamixaban

Chemical Properties

CAS No. :	193153-04-7
Formula:	C ₂₅ H ₂₆ N ₄ O ₄
Molecular Weight:	446.5
Appearance:	no data available
Storage:	store at low temperature Powder: -20°C for 3 years In solvent: -80°C for 1 year



Biological Description

Description	Otamixaban (FXV673) is a selective and highly effective Xa inhibitor that inhibits the generation of thrombin and can be used to study acute coronary syndrome.
Targets(IC50)	Factor Xa
In vitro	The HTS assay indicates that otamixaban shows inhibitory activity against TMPRSS2. IC ₅₀ = 18.7 × 10 μM. Otamixaban in the Calu-3 cell line inhibits SARS-CoV-2 S-mediated viral entry. [5]
In vivo	Otamixaban is highly efficacious in rodent, canine and porcine models of thrombosis showed in vivo experiments. Recent clinical findings indicate that Otamixaban is efficacious, safe, and well-tolerated in humans and therefore has considerable potential for the treatment of acute coronary syndrome.

Solubility Information

Solubility	DMSO: 40 mg/mL (89.59 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	--

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.2396 mL	11.1982 mL	22.3964 mL
5 mM	0.4479 mL	2.2396 mL	4.4793 mL
10 mM	0.224 mL	1.1198 mL	2.2396 mL
50 mM	0.0448 mL	0.224 mL	0.4479 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

- Eikelboom JW, Weitz JI. Otamixaban in acute coronary syndromes. Lancet. 2009 Sep 5;374(9692):762-4. Epub 2009 Aug 28.
- Sabatine MS, Antman EM, et al. Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial. Lancet. 2009 Sep 5;374(9692):787-95. Epub 2009 Aug 28
- Guertin KR, Choi YM. The discovery of the Factor Xa inhibitor otamixaban: from lead identification to clinical development. Curr Med Chem. 2007;14(23):2471-81.
- Cohen M, Bhatt DL, et al. SEPIA-PCI Trial Investigators. Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial. Circulation. 2007
- Guertin, Kevin R.; Choi, Yong-Mi. The discovery of the factor Xa inhibitor Otamixaban: from lead identification to clinical development. Current Medicinal Chemistry (2007), 14(23), 2471-2481.
- Hempel T, et al. Synergistic inhibition of SARS-CoV-2 cell entry by otamixaban and covalent protease inhibitors: pre-clinical assessment of pharmacological and molecular properties. Chem Sci. 2021 Aug 26;12(38):12600-12609.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only. Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E_mail: info@targetmol.com Address: 36 Washington Street, Wellesley Hills, MA 02481